FINAL outcome ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-positive breast cancer PATIENTS WITH active brain metastases.
Rupert BartschAnna Sophie BerghoffJulia FurtnerMaximilian MarholdElisabeth Sophie BergenSophie Roider-SchurMaximilian Johannes MairAngelika Martina StarzerHeidrun ForstnerBeate RottenmannerMarie-Bernadette AretinKarin DieckmannZsuzsanna Bago-HorvathHelmuth HaslacherGeorg WidhalmAysegül Ilhan-MutluChristoph MinichsdorferThorsten FuerederThomas SzekeresLeopold OehlerBirgit GruenbergerGeorg PfeilerChristian SingerAnsgar WeltermannLuzia BerchtoldMatthias PreusserPublished in: Neuro-oncology (2024)
T-DXd yielded prolonged intra- and extracranial disease control in patients with active HER2-positive BC BM in line with results from the pivotal trials. These results support the concept of ADCs as systemic therapy for active BM.